Biopharmaceutical company Bristol Myers Squibb (NYSE: BMY) on Wednesday reported preliminary results from two Phase 3 studies evaluating investigational drug KarXT (xanomeline and trospium chloride) for psychosis associated with Alzheimer's disease, showing improvements in hallucinations, delusions and overall disease severity, with no new safety signals.
Data from the 12-week open-label lead-in of ADEPT-1 showed a mean 12-point reduction in hallucination and delusion scores from a baseline of 14.4 among 266 participants. Disease severity scores also improved, declining by a mean 1.9 points from 4.5. Of 320 participants enrolled, 85.3% completed the treatment period.
In the 52-week ADEPT-3 open-label extension, involving 401 participants, 68.1% completed treatment. Mean hallucination and delusion scores declined by 5.1 points from a baseline of 8.9, while disease severity scores improved by 0.8 points from 3.4. KarXT was generally well tolerated, with treatment-related adverse events leading to discontinuation in 4.7% of participants.
The findings, presented at the Clinical Trials on Alzheimer's Disease conference in Boston, represent the first clinical data disclosed from the ADEPT Phase 3 programme. Both studies remain ongoing, with results from their double-blind treatment periods still blinded.
KarXT, marketed as Cobenfy for schizophrenia in adults in the US, remains investigational for Alzheimer's-related psychosis. The wider ADEPT programme includes additional studies assessing acute efficacy and dosing.
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment